EVENTS | VIEW CALENDAR
Samsung Bioepis a step closer to marketing Humira biosimilar in Europe
INCHEON, Korea—Mid-July saw Samsung Bioepis Co. Ltd. announce that the European Medicines Agency (EMA) had accepted for review the company’s Marketing Authorization Application (MAA) for SB5, a biosimilar candidate referencing Humira (adalimumab).
SB5 is Samsung Bioepis’ third anti-TNF-α biosimilar candidate submitted for review to the EMA, following Benepali (etanercept) and Flixabi (infliximab), both of which have since received European Commission approval—in January 2016 and May 2016, respectively.
Should the MAA get EMA’s official approval, the marketing and distribution of SB5 in Europe will be handled by Biogen.
“If approved, SB5 will join Benepali and Flixabi in Europe, which have already started to increase patient access to high-quality treatment options while driving down healthcare spending,” said Christopher Hansung Ko, president and CEO of Samsung Bioepis. “We will continue to work hard to advance one of the industry’s largest biosimilar pipelines, so that more patients can access affordable medicines without any compromise in the quality of treatment.”
The MAA for SB5 was based on data derived from a 52-week Phase 3 study which randomized 544 patients with moderate to severe rheumatoid arthritis despite methotrexate therapy. The 24-week results showed ACR20 response rate of 72.5 percent in the SB5 arm versus 72 percent in the adalimumab arm, while the safety profile of SB5 was comparable to adalimumab. At week 24, 508 patients with rheumatoid arthritis were randomized in a 1:1 ratio to receive either SB5 or adalimumab 40 mg every other week via subcutaneous injection—254 patients from SB5 continued to receive SB5 (SB5/SB5), 125 patients from adalimumab were transitioned to SB5 (adalimumab/SB5) and 129 patients from adalimumab continued to receive adalimumab (adalimumab/adalimumab).
At week 52, the efficacy, safety and immunogenicity profiles remained comparable between SB5/SB5, adalimumab/SB5 and adalimumab/adalimumab with ACR20 response rates of 76.9 percent, 81.1 percent and 71.2 percent, respectively. There were no treatment emergent issues or clinically relevant immunogenicity precipitated by switching. After transition up to week 52, the incidence of anti-drug antibody was 15.7 percent in SB5/SB5, 16.8 percent in adalimumab/SB5 and 18.3 percent in adalimumab/adalimumab.
Samsung Bioepis continues to advance a broad pipeline of 13 biosimilar candidates, which includes the following six first-wave candidates that cover the therapeutic areas of immunology, oncology and diabetes:
Samsung Bioepis is responsible for the development and manufacture of all immunology and oncology biosimilar candidates in its pipeline, as well as global clinical trials and regulatory registration in all markets worldwide for these biosimilar candidates. Following approval, Samsung Bioepis biosimilar products are marketed and distributed by its commercialization partners, Merck and Biogen.
Samsung Bioepis and Biogen have a manufacturing partnership for anti-TNF-α biosimilars, which brings together Samsung Bioepis’ technical leadership in manufacturing process development and Biogen’s expertise in manufacturing biologics. Samsung Bioepis’ biosimilars are manufactured in the same state-of-the-art drug substance facilities that have manufactured Biogen’s biologic medicines.